BPC-157 — Reconstitution & Dosage Calculator

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a larger protective protein naturally present in human gastric juice. First characterized in the early 1990s by researchers at the University of Zagreb School of Medicine, BPC-157 has since become one of the most extensively studied peptides in preclinical regenerative research.

Unlike most peptide research compounds, BPC-157 is remarkably stable at physiological pH and resistant to enzymatic degradation in the gastrointestinal tract — properties that distinguish it from growth-hormone secretagogues like Ipamorelin or CJC-1295 and have made it a subject of interest for both injectable and oral administration routes in laboratory settings. With over 168 publications indexed in PubMed, it has been investigated across tissue repair, gastrointestinal protection, cardiovascular function, and neuroprotection models.

Research Context

Evidence Level: The following summarizes findings from peer-reviewed preclinical studies (animal models and in vitro experiments). No large-scale human clinical trials have been completed to date. Findings should not be interpreted as clinical recommendations.

Overview

BPC-157 research spans roughly three decades, with the majority of published work originating from the University of Zagreb group led by Predrag Sikiric. The literature encompasses over 100 original studies and multiple narrative reviews, predominantly conducted in rodent models. Research clusters around four major themes: musculoskeletal tissue repair, gastrointestinal cytoprotection, vascular growth modulation, and organ-protective effects. Evidence maturity varies — tendon and GI healing data are the most replicated, while cardiovascular and neurological findings remain preliminary.

Musculoskeletal Tissue Repair

Tendon and ligament healing represents the most extensively studied application of BPC-157. In a foundational study using rat Achilles tendon transection models, Chang et al. (2011) demonstrated that BPC-157 promoted tendon outgrowth, increased fibroblast survival, and accelerated cell migration — effects mediated through upregulation of FAK (focal adhesion kinase) and paxillin phosphorylation, key proteins in the cell migration signaling pathway. F-actin formation assays revealed dose-dependent cytoskeletal reorganization essential for cell motility, while Western blot analysis confirmed sustained phosphorylation of paxillin at injury sites. These findings were consistent with earlier work showing enhanced collagen deposition and reticulin formation at injury sites.

A comprehensive review by Gwyer et al. (2019) in Cell and Tissue Research (45 citations) synthesized evidence across multiple musculoskeletal soft tissue models, concluding that BPC-157 outperformed standard growth factors (bFGF, EGF, VEGF) in promoting connective tissue repair without requiring biocompatible carriers — a significant practical advantage. The review highlighted BPC-157’s unique stability profile, which eliminates the need for complex delivery systems that often limit clinical translation of other growth factors.

More recently, a systematic review in orthopaedic sports medicine by Vasireddi et al. (2025) confirmed these preclinical findings and noted growing off-label use among clinicians and athletes, despite the absence of FDA approval. A 2026 review in the American Journal of Sports Medicine by Mayfield et al. positioned BPC-157 alongside TB-500 as a leading candidate in injectable peptide therapy for orthopaedic injuries, emphasizing the need for controlled human trials.

A retrospective clinical observation by Lee et al. (2021) reported on intra-articular BPC-157 injections for multiple types of knee pain, including osteoarthritis and meniscus tears, representing one of the few published human-use case series — though the study design (retrospective, uncontrolled) limits the strength of its conclusions.

Wound Healing and Cytoprotection

BPC-157’s cytoprotective properties extend beyond musculoskeletal tissue. Seiwerth et al. (2021) published a detailed review in Frontiers in Pharmacology (39 citations) covering skin wound therapy across incisional wounds, excisional wounds, deep burns, diabetic ulcers, and alkali burns. The authors highlighted BPC-157’s dose-dependent stimulation of angiogenesis via VEGFR2 upregulation and its ability to promote fibroblast proliferation and F-actin formation — mechanisms that accelerate wound closure across multiple tissue types.

In the gastrointestinal tract, BPC-157 has demonstrated protective effects against NSAID-induced gastric ulceration, with studies showing preservation of mucosal integrity through enhanced nitric oxide generation and modulation of the prostaglandin system. This is particularly notable given that BPC-157 is itself derived from gastric juice proteins, suggesting an endogenous protective role.

Vascular Growth and Cardiovascular Protection

A major review by Seiwerth et al. (2019) in Current Pharmaceutical Design (76 citations) — the most-cited paper in this dataset — positioned BPC-157 as a unique angiogenic agent that operates through the VEGFR2/nitric oxide signaling axis. Unlike standard growth factors that require carrier systems for in vivo stability, BPC-157 demonstrated comparable or superior angiogenic effects when administered alone across gastrointestinal, tendon, ligament, muscle, and bone healing models.

Cardiovascular applications were explored by Sikiric et al. (2022) in Biomedicines, reviewing BPC-157’s effects across myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis models. The proposed mechanism involves direct endothelial cell protection combined with promotion of collateral blood vessel formation around ischemic zones — a process termed vascular “running” that could theoretically reduce the need for surgical revascularization. These findings remain limited to rodent models.

Antioxidant and Cytoprotective Properties

BPC-157 demonstrates significant antioxidant activity through modulation of reactive oxygen species (ROS) and nitric oxide pathways. Studies in rodent models have shown that BPC-157 reduces oxidative stress markers including malondialdehyde (MDA) and nitric oxide metabolites in gastrointestinal tissue. This antioxidant capacity appears to contribute to its broader cytoprotective effects, particularly in protecting cells from NSAID-induced damage and ischemia-reperfusion injury.

The peptide’s ability to maintain cellular redox balance while simultaneously promoting angiogenesis represents a unique dual mechanism — most antioxidants suppress angiogenesis, whereas BPC-157 enhances it. This property may explain its efficacy across diverse tissue types and injury models.

Drug Side Effect Mitigation

An emerging research direction involves BPC-157’s potential to counteract pharmaceutical side effects. Preclinical studies have demonstrated protective effects against NSAID-induced gastric bleeding, QTc prolongation from psychiatric medications, and various cardiovascular drug toxicities. In rat models, BPC-157 prevented drug-induced catalepsy and somatosensory disturbances without interfering with the primary therapeutic effects of the medications.

This application could have significant clinical implications, as medication side effects are a leading cause of treatment discontinuation in chronic disease management. However, all evidence remains limited to animal models, and drug-drug interaction studies in humans have not been conducted.

Emerging Research Directions

A 2025 literature and patent review by Jóźwiak et al. in Pharmaceuticals provided the most comprehensive overview to date, covering BPC-157’s pleiotropic effects across tissue injury, inflammatory bowel disease, and CNS disorders. The authors noted that BPC-157 was temporarily banned by the World Anti-Doping Agency in 2022 (though not currently listed), reflecting its perceived performance-enhancing potential. A parallel editorial in Arthroscopy by DeFoor et al. (2025) framed BPC-157 as a frontrunner among injectable therapeutic peptides in regenerative sports medicine, citing early pharmacokinetic data suggesting optimization of endurance training, metabolism, and recovery.

An early pilot study by Lee et al. (2024) explored BPC-157 for interstitial cystitis (bladder pain syndrome), a condition with limited treatment options — representing a novel application outside the traditional musculoskeletal and GI domains. A separate safety study by Lee et al. (2025) assessed intravenous BPC-157 infusion in two human participants (10 mg and 20 mg doses), reporting no adverse effects on vital signs or blood chemistry — the first published data on IV administration in humans.

The most recent comprehensive review by Yuan et al. (2026) in International Journal of Molecular Sciences expanded the evidence base to include pain modulation mechanisms, noting that BPC-157 may influence peripheral and dopaminergic pain pathways in addition to its tissue repair properties.

Methodological Observations

The BPC-157 literature is characterized by several consistent patterns: the majority of studies use small-sample rodent models (primarily rats), with subcutaneous or intraperitoneal administration routes. Dosing ranges typically fall between 10–50 µg/kg in animal studies. The University of Zagreb group authored a disproportionate share of publications, which, while reflecting deep expertise, also means that independent replication from other laboratories remains limited. In vitro studies consistently use fibroblast and endothelial cell cultures, with F-actin formation and VEGFR2 expression as primary endpoints.

Research Gaps and Limitations

• Evidence level gap — No randomized controlled trials (RCTs) in humans have been completed. The Lee et al. knee pain study (2021) and interstitial cystitis pilot (2024) are retrospective/uncontrolled observations, not clinical trials.
• Methodological gap — Sample sizes are small (typically n=6–12 per group), follow-up periods are short, and dose-response relationships across different tissue types are not well characterized.
• Translational gap — Animal-to-human dose extrapolation lacks validation. The commonly cited rodent doses (10–50 µg/kg) cannot be directly scaled to human equivalents without pharmacokinetic bridging studies.
• Safety gap — While no toxicity has been reported (LD1 not achieved in animal studies), long-term safety data beyond 12-week exposure periods are absent.
• Independence gap — The field would benefit from more replication studies by research groups outside the University of Zagreb.

Reconstitution Mathematics

Accurate reconstitution is critical for consistent dosing in any laboratory protocol. The interactive calculator on this page handles all the arithmetic — but understanding the underlying formula is useful for verification:

Concentration (mg/mL) = Vial Size (mg) ÷ BAC Water Added (mL)
Dose Volume (mL)      = Desired Dose (mg) ÷ Concentration (mg/mL)
Syringe Units (IU)    = Dose Volume (mL) × 100   [for U-100 insulin syringe]

Common laboratory reconstitution examples:

Use the interactive calculator on this page for any custom vial size, water volume, or dose.

Common Research Dosing Parameters

Based on published preclinical literature. These are not clinical recommendations.

The following table summarizes dosing parameters reported across published BPC-157 animal studies:

Key observations from the literature:

• Subcutaneous (SC) and intraperitoneal (IP) routes showed comparable efficacy in most tendon and GI models
• BPC-157’s stability at gastric pH enables oral bioavailability — unusual among peptides
• No dose-limiting toxicity was reported at any tested dose level (LD1 not achieved)
• Most published study designs used once-daily administration

Graduated Dosing Design from Published Studies

The following graduated design reflects dosing escalation patterns observed across multiple published rodent studies. It is not a clinical protocol.

Reconstitution assumption: 5 mg vial + 2 mL BAC water = 2.5 mg/mL concentration

*Example doses calculated for illustrative purposes based on common vial configurations.

Dose range sources:

• 10 µg/kg — low-dose baseline used in Seiwerth et al. (2018) and Gwyer et al. (2019)
• 25–50 µg/kg — standard range in tendon models by Chang et al. (2011) and GI protection studies reviewed in Sikiric et al. (2022)
• 50–100 µg/kg — high-dose extended studies reviewed in Jóźwiak et al. (2025); no dose-limiting toxicity reported (LD1 not achieved)

Important notes:

• Dose values are derived from published rodent literature and represent per-kilogram body weight
• Human dose extrapolation requires allometric scaling and pharmacokinetic validation, which has not been performed
• The majority of published studies used subcutaneous administration; oral bioavailability has been demonstrated but with less consistent dosing data
• IU values assume a U-100 insulin syringe (1 IU = 0.01 mL)

Stability & Storage

Bacteriostatic water (BAC water, 0.9% benzyl alcohol) is the standard diluent for reconstitution because benzyl alcohol acts as a preservative, extending the usable life of the reconstituted solution.

Reconstitution procedure (standard laboratory protocol):

1. Allow vial to reach room temperature (~15 minutes)
2. Wipe septum with 70% isopropyl alcohol
3. Draw desired BAC water volume into a sterile syringe
4. Insert needle at a 45° angle and inject slowly along the vial wall — do not inject directly onto the lyophilized cake
5. Gently swirl (do not shake or vortex) until fully dissolved
6. Label vial with date, concentration, and store per table above

Frequently Asked Questions

How many units do I draw for 250 mcg of BPC-157?

It depends on your reconstitution ratio. With a 5 mg vial in 2 mL BAC water (2.5 mg/mL concentration), a 250 mcg dose = 10 units on a U-100 insulin syringe. With 5 mL BAC water instead, the same dose = 25 units. Use the calculator above for your specific setup.

Can BPC-157 be combined with TB-500 in the same syringe?

In laboratory settings, BPC-157 is frequently studied alongside TB-500 (Thymosin Beta-4) for complementary tissue repair mechanisms. Their stability profiles are compatible in bacteriostatic water. Use the multi-peptide mode to compute combined injection volumes and verify total draw does not exceed syringe capacity.

What is the difference between BPC-157 Acetate and BPC-157 Arginine Salt?

The arginine salt form has improved water solubility and dissolves faster during reconstitution. Both contain the same active 15-amino-acid sequence — the counterion (acetate vs. arginine) affects dissolution speed but not the reconstitution mathematics or concentration calculations.

How long does reconstituted BPC-157 last in the refrigerator?

Reconstituted in bacteriostatic water and stored at 2–8 °C, BPC-157 remains stable for up to 28 days. Always use a fresh alcohol swab on the vial septum before each draw. If the solution becomes cloudy or discolored, discard it.

Is BPC-157 orally bioavailable?

Unlike most peptides, BPC-157 is stable at physiological pH and resistant to gastric acid degradation. Published rodent studies have demonstrated efficacy via oral administration at comparable doses to injectable routes — a property that distinguishes it from peptides like Ipamorelin or GHRP-6 which require injection.

What concentration is standard for BPC-157 laboratory protocols?

Published rodent studies most commonly use doses expressed per kilogram body weight (10–50 µg/kg). For reconstitution purposes, a 5 mg vial in 2 mL BAC water (2.5 mg/mL) is the most common configuration. The calculator above supports any custom combination.

Does BPC-157 require refrigeration after reconstitution?

Yes. Once reconstituted with bacteriostatic water, BPC-157 should be stored at 2–8 °C (refrigerator) and used within 28 days. The lyophilized powder can be stored at −20 °C for 24+ months. Always allow refrigerated solutions to reach room temperature before injection to minimize discomfort.

Can BPC-157 be used alongside other peptides like TB-500 or Ipamorelin?

In research settings, BPC-157 is frequently studied in combination with TB-500 for synergistic tissue repair effects. Their mechanisms are complementary — BPC-157 promotes angiogenesis and fibroblast migration, while TB-500 enhances actin polymerization and cell differentiation. Growth hormone secretagogues like Ipamorelin or CJC-1295 operate through different pathways (GH/IGF-1 axis) and are sometimes studied concurrently. Use the multi-peptide calculator to compute combined volumes.

FOR RESEARCH PURPOSES ONLY. Not for human consumption. Not for veterinary use. Not a drug, food, or cosmetic.